Skip to content

Released Nov 3, 2026, before the open

10-Q filed Nov 3, 2026, 37 days after period end · 0000078003-26-000127

Q3 2026 · 10-Q
Revenue$16.58B−0.4% vs Q3 2025+10.3% vs Q2 2026
Net Income$3.24B−8.4% vs Q3 2025N/M vs Q2 2026
EPS Diluted$0.56−9.7% vs Q3 2025N/M vs Q2 2026
Operating Cash Flowderived$5,375,000,000+16.8%
Free Cash Flowderived$4,802,000,000+20.0%
Margins · derived
Net margin19.6%−1.7 pt vs Q3 2025

What the release said

On November 3, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the third quarter of 2026.

Pfizer reported third-quarter 2026 revenues of $16.6 billion, relatively flat year-over-year operationally, with reported diluted EPS of $0.56 and Adjusted diluted EPS of $0.87.2

Pfizer raised full-year 2026 revenue guidance by $1.5 billion at the midpoint to a range of $62.0 to $64.0 billion, and raised and narrowed Adjusted diluted EPS guidance to $2.95 to $3.05.234

The 2026 Adjusted diluted EPS guidance includes a one-time $650 million Acquired In-Process R&D charge tied to the Innovent Biologics, Inc. in-licensing and collaboration agreement, with an unfavorable impact of approximately $0.10.5

Pfizer returned $7.3 billion of cash dividends, or $1.29 per share, in the first nine months of 2026, and has completed no share repurchases to date in 2026.67

Third-quarter Eliquis revenues rose $513 million, or 25%, operationally, while Paxlovid revenues fell $771 million, or 63%, operationally.89

Third-quarter 2026 revenues
$16.6 Billion2
Third-quarter 2026 Reported diluted EPS
$0.562
Third-quarter 2026 Adjusted diluted EPS
$0.87 Third-Quarter 2026; same as the prior-year quarter2
Full-year 2026 revenue guidance
$62.0 to $64.0 billion Raised by $1.5 billion at the midpoint, from $60.5 to $62.5 billion previously3
Full-year 2026 Adjusted diluted EPS guidance
$2.95 to $3.05 Raised and narrowed from $2.80 to $3.00 previously4
Innovent in-licensing charge
$650 million One-time Acquired In-Process R&D charge recorded in the third quarter of 20265
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$16.58B$16.65B$17.70B$13.49B
Net Income$3.24B$3.54B$4.47B-$2.38B
EPS Diluted$0.56$0.62$0.78-$0.42

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR